Abstract resume

, ,
,
, 5
.
.
, 50%
,
.

, , ,
.
- Keywords: Peripartum cardiomyopathy; Peripartum heart failure;
Pregnancy-associated cardiomyopathy
by
.


. .
...

,
,
, 5
, .

, .
.
1849 Ritchie1
19372, (degeneration),
,
.
1997, National Heart, Lung, and Blood Institute (NHLBI)
Office of Rare Diseases of the National Institutes of Health (NIH)

. , , ,

, , , ,
, ,

.

-

.
1:4000 ()3 750
. .
, 1:10004, , ,
1:2995 , ,
1:1006.

 (
)
(
).
,
- .

1971 Demakis 7 27
Cook
County Hospital, 1947 1967, Chicago, IL.

, 1997, National
Heart Lung and Blood Institute and Office of Rare Disease Workshop (2000)3

.

.
.


,
.
4 National Heart Lung
and Blood Institute and the Office of Rare Diseases (Bethesda, MD) (Pearson et al.
2000):
1.
2.
3.
4.

6


:
EF < 45%,
FS < 30% /
LVEDD>2,7 cm/m2

- ()

, , ,

.
8

9
10
11

12
13
14
15

: Karen Sliwa, James Fett, Uri Elkayam. Peripartum cardiomyopathy,

Seminar, Lancet 2006;368:68769316
( )
:
, , , ,
, , ,
, .17

,
. (
,
.. ...)
.

.14 .

 (
8,8% 78%
).

.


(
graft versus host disease, GVHD).18,19
.
9%
.


.
stress
(proteolytic cleavage)
- (antiangiogenic), (proapoptotic) .20

.
,
( D2 )

.

, SLE, ,
,
).21,22
,

(registry) ,
o

 ,
lifestyle .

23

.
.

, , .
:
, , ,
.
: ,
, (64%), (50%),
(35-85%, 100%),
, ,
.

S2

24

,
.
NYHA
I IV.
, ,
.

 : , ,
, .

( ,
,
). ,
, Q QS, ,
ST QTc.
(50%):
. ( ,
)
( ),

.
.
.
(7-50%):
,

.


.

.
.

. .
.
( )
.
. .


,
LVEDP .

,
D-dimers.
, , ,
, , HIV,
,

.


( ,
, )
( )
( )


.

.

.

, , (
),
,
(..
).

.
. ,
,

 .

( )
(, , ).
.
, .

( , ,
)
( ).
.
.
: -
1 .

30%.
,
.

15 25%. 3 .
1/3

. 50% ,

.
20%
6 cm
.25

(follow-up).



. ,
,

.26

.27

Ritchie C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases in the heart. Edinburgh Med Surg J 1849;2:333
2
Gouley BA, McMillan TM, Bellet S. diopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci. 1937;19: 185-199
3
Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy. National Heart, Lung, and Blood Institute and
Offi ce of Rare Diseases (National Institutes of Health) Workshop ecommendations and review. JAMA 2000; 283: 1183
88
4
Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South
Africa and a review of the literature. Trop Doct 1995; 25: 11823
5
Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum
cardiomyopathy at a single institution. Mayo Proceed 2005; 80: 160206
6
Davidson NM, Parry EH. Peri-partum cardiac failure. Q J Med 1978;47:43161
7
Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation 1971;44:1053
61
8
Podewski E, Hilfi ker A, Hilfi ker-Kleiner D, Kaminski K, Drexler H. Stat 3 protects female hearts from postpartum cardiomyopathy in the mouse: the potential role of prolactin (abstract 2178). Munich:
European Society of Cardiology Meeting, 2004.
9
Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dys function. Circulation 2005; 112: 196570.
10
Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/Apo-1.
J Am Coll Cardiol 2000; 35: 70105.
11
Ansari AA, Fett JD, Carraway RD, Mayne AE, Onlamoon M, Sundstrom JB. Autoimmune mechanisms as the basis for
human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002; 23: 289312.
12
Fett JD, Sundstrom JB, Ansari AA, Combs GF Jr. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol 2002; 86: 31115
13
Hayakawa Y, Chandra M, Wenfeng M, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in peripartum cardiomyopathy of G(q) transgenic mice.
Circulation 2003; 108: 1037-42.
14
Hilfiker-Kleiner D, Kaminski K, Podewski E, et al: 2007a. A cathepsin D-cleaved 16-kDa
form of prolactin mediates postpartum cardiomyopathy. Cell 128:589600.
15
Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al: 2007b. Recovery from postpartum cardiomyopathy
in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 50:23542355.
16
Karen Sliwa, James Fett, Uri Elkayam. Peripartum cardiomyopathy, Seminar, Lancet 2006;368:687693
17
Edited by Celia Oakley: in WOMEN & HEART DISEASE 2nd Ed, Nanette Kass Wenger, Peter Collins. 2005 Taylor &
Francis, Ch. 25, p. 341-373
18
Gleicher N. Graft-versus host disease and immunologic rejection: implications for diagnosis and treatments of pregnancy
complications. Expert Rev Obstet Gynecol 2008;3:3749.
19
Gleicher N, Elkayam U, Peripartum cardiomyopathy, an autoimmune manifestation of allograft
rejection? Autoimmun Rev (2008), doi:10.1016/j.autrev.2008.12.003
20
Denise Hilfiker-Kleiner, Karen Sliwa, and Helmut Drexler. Peripartum Cardiomyopathy: Recent
Insights in its Pathophysiology Trends Cardiovasc Med 2008;18:173179
21
Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmune Rev 2002;1:3604
22
Orbacj H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmune Rev 2007;6:53742
23
Edited by Celia Oakley: Celia Oakley, Carole A Warnes in Heart Disease in Pregnancy, 2nd Ed, 2007 by Blackwell
Publishing, Ch. 14 p.186-197
24
S. Fennira *, A. Demiraj, A. Khouaja, M.-R. Boujnah. La cardiomyopathie du pripartum - Peripartum cardiomyopathy
Annales de Cardiologie et dAngiologie 2006;55: 271275
25
Withlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: a longitudinal echocardiographic study. Am J Obstet
Gynecol 1997;177:112932
26
Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM. Contractile reserve in patients with peripartum
cardiomyopathy and recovered left ventricular function dysfunction. Am J Obstet Gynecol 1997;176:18995
27
Elkayam U, Padmini P, Tummala P, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001; 344: 156771